瑞巴派特联合三联疗法治疗消化性溃疡疾病的临床效果评价

Evaluate clinical effect of rebamipide combined with triple therapy in treatment of peptic ulcer disease

目的探讨瑞巴派特联合三联疗法治疗消化性溃疡疾病的临床价值。方法选取2012年1月~2016年12月收治的120例消化性溃疡患者作为研究对象,随机分为观察组和对照组,每组各60例,对照组常规应用三联疗法(质子泵抑制剂、幽门螺杆菌阳性者加克拉霉素及阿莫西林),观察组在对照组的基础上加瑞巴派特。结果治疗前两组消化性溃疡患者各临床症状积分比较无显著性差异(P>0.05),治疗以后两组均下降,观察组上腹痛、反酸、腹胀、嗳气低于对照组(P<0.05),观察组胃镜检查总有效率高于对照组(P<0.05),观察组复发率低于对照组(P<0.05)。结论采用瑞巴派特联合三联疗法治疗消化性溃疡,能够有效改善患者临床症状,提高治疗总有效率,降低复发率降,未发现明显不良反应。

Objective To investigate the clinical value of rebamipide combined with triple therapy in treatment of peptic ulcer disease. Methods 120 patients with peptic ulcer were randomly divided into observation group and control group with 60 cases in each group, the control group used conventional triple therapy（proton pump inhibitors, Helicobacter pylori positive patients with amoxicillin and clarithromycin, observation group in the control group based on rebamipide. Results Before treatment the clinical symptoms of the two groups of patients with peptic ulcer score showed no significant difference（P〈0.05）. The two groups were decreased after treatment, the observation group of upper abdominal pain, acid reflux,abdominal distension, belching is lower than the control group（P〉0.05）. The total effective observation group gastroscopy higher than the control group（P〈0.05）. The observation group recurrence rate was lower than that in the control group 33.33%（P〈0.05）. Conclusion For patients with peptic ulcer by rebamipide combined with triple therapy, can effectively improve the clinical symptoms and improve the total efficiency of treatment, reduce the recurrence rate, no obvious adverse reactions.